The Pharmaceutical Benefits Scheme (PBS) listing for aflibercept was expanded on 1 October 2020. Aflibercept is now subsidised for the treatment of subfoveal choroidal neovascularisation, in addition to macular oedema secondary to diabetes or retinal vein occlusion.

Aflibercept binds vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) to prevent their interaction with VEGF receptors. Excessive activation of VEGF receptors is associated with pathologic angiogenesis and increased vascular permeability. Interruption of these pathways by aflibercept can slow vision loss by reducing vascular leakage and neovascularisation.

Aflibercept is administered by ophthalmologists as an intravitreal injection. Following administration, patients must be monitored for increased intraocular pressure. Patients should also be advised to seek immediate medical advice if they experience any symptoms indicative of endophthalmitis such as eye pain or redness, photophobia, or blurred vision.


  1. Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: what’s new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacological Research 2016; 103: 253-69.
  2. Eylea® (Aflibercept) Australian approved product information. Pymble: Bayer Australia. Approved July 2020.
  3. Hye-Rong Shim A, Liu H, Focia PJ, Chen X, Lin PC, He X. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proceedings of the National Academy of Sciences 2010; 107(25): 11307-12.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates